-- Scott Roberts
MONDAY, Feb. 13 (HealthDay News) -- Merck's Zioptan drops
(tafluprost ophthalmic solution) has been approved by the U.S. Food
and Drug Administration to lower pressure within the eye among
people with high blood pressure of the eye (ocular hypertension) or
open-angle glaucoma, the most common form of the disease.
Approval was based on five clinical studies involving 905
people, the drug's maker said in a news release. The most common
side effects included increased pigmentation of the iris and
eyelids, and changes in the thickness and color of the
The product should not be used by children or by pregnant women,
Merck warned. It also should be used "with caution" among nursing
women and by people with macular swelling (edema).
Zioptan should be on pharmacy shelves in March, the Whitehouse
Station, N.J., company said.
Medline Plus has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.